Vildagliptin-13C5,15N is a stable isotope-labeled version of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. This compound is used in pharmaceutical research for the treatment of type 2 diabetes by increasing insulin secretion and decreasing glucagon release. The incorporation of carbon-13 and nitrogen-15 isotopes makes it ideal for metabolic studies, pharmacokinetics, and tracing experiments. Vildagliptin-13C5,15N helps researchers analyze the drug’s absorption, distribution, metabolism, and excretion, providing critical insights into its mechanism of action and potential therapeutic effects.
| Catalog Number | R042874 |
| CAS Number | 1044741-01-6 |
| Synonyms | (2S)-1-[2-[(3-Hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-2-pyrrolidinecarbonitrile-13C5,15N; LAF 237-13C5,15N; NVP-LAF 237-13C5,15N; Galvus-13C5,15N; |
| Molecular Formula | C17H25N3O2 |
| Purity | 95% |
| Storage | -20°C |
| IUPAC Name | (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile |
| InChI | InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1/i1+1,2+1,3+1,9+1,14+1,20+1 |
| InChIKey | SYOKIDBDQMKNDQ-AXHOPKHVSA-N |
| SMILES | C1C2CC3(CC1CC(C2)(C3)O)NCC(=O)[15N]4[13CH2][13CH2][13CH2][13C@H]4[13C]#N |
